Literature DB >> 16041052

Protection against aerosolized Yersinia pestis challenge following homologous and heterologous prime-boost with recombinant plague antigens.

Audrey Glynn1, Chad J Roy, Bradford S Powell, Jeffrey J Adamovicz, Lucy C Freytag, John D Clements.   

Abstract

A Yersinia pestis-derived fusion protein (F1-V) has shown great promise as a protective antigen against aerosol challenge with Y. pestis in murine studies. In the current study, we examined different prime-boost regimens with F1-V and demonstrate that (i) boosting by a route other than the route used for the priming dose (heterologous boosting) protects mice as well as homologous boosting against aerosol challenge with Y. pestis, (ii) parenteral immunization is not required to protect mice against aerosolized plague challenge, (iii) the route of immunization and choice of adjuvant influence the magnitude of the antibody response as well as the immunoglobulin G1 (IgG1)/IgG2a ratio, and (iv) inclusion of an appropriate adjuvant is critical for nonparenteral immunization.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16041052      PMCID: PMC1201190          DOI: 10.1128/IAI.73.8.5256-5261.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  32 in total

1.  Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL.

Authors:  I M Belyakov; J D Ahlers; J D Clements; W Strober; J A Berzofsky
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

2.  Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming.

Authors:  M C Gagliardi; F Sallusto; M Marinaro; A Langenkamp; A Lanzavecchia; M T De Magistris
Journal:  Eur J Immunol       Date:  2000-08       Impact factor: 5.532

3.  Evaluation of a truncated recombinant flagellin subunit vaccine against Campylobacter jejuni.

Authors:  L H Lee; E Burg; S Baqar; A L Bourgeois; D H Burr; C P Ewing; T J Trust; P Guerry
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

4.  Effectiveness of intranasal immunization with HIV-gp160 and an HIV-1 env CTL epitope peptide (E7) in combination with the mucosal adjuvant LT(R192G).

Authors:  C B Morris; E Cheng; A Thanawastien; L Cárdenas-Freytag; J D Clements
Journal:  Vaccine       Date:  2000-03-17       Impact factor: 3.641

5.  Adjuvant activity of a nontoxic mutant of Escherichia coli heat-labile enterotoxin on systemic and mucosal immune responses elicited against a heterologous antigen carried by a live Salmonella enterica serovar Typhimurium vaccine strain.

Authors:  H C Guillobel; J I Carinhanha; L Cárdenas; J D Clements; D F de Almeida; L C Ferreira
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

6.  Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA.

Authors:  S Gerber; C Lane; D M Brown; E Lord; M DiLorenzo; J D Clements; E Rybicki; A L Williamson; R C Rose
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

7.  Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection.

Authors:  T M Tumpey; M Renshaw; J D Clements; J M Katz
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

8.  Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection.

Authors:  K L Kotloff; M B Sztein; S S Wasserman; G A Losonsky; S C DiLorenzo; R I Walker
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

9.  Intranasal administration of 2/6-rotavirus-like particles with mutant Escherichia coli heat-labile toxin (LT-R192G) induces antibody-secreting cell responses but not protective immunity in gnotobiotic pigs.

Authors:  L Yuan; A Geyer; D C Hodgins; Z Fan; Y Qian; K O Chang; S E Crawford; V Parreño; L A Ward; M K Estes; M E Conner; L J Saif
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

10.  Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants.

Authors:  T Scharton-Kersten; J m Yu; R Vassell; D O'Hagan; C R Alving; G M Glenn
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

View more
  25 in total

1.  Primary pneumonic plague in the African Green monkey as a model for treatment efficacy evaluation.

Authors:  R Colby Layton; Trevor Brasel; Andrew Gigliotti; Edward Barr; Steven Storch; Leslie Myers; Charles Hobbs; Frederick Koster
Journal:  J Med Primatol       Date:  2010-08-16       Impact factor: 0.667

2.  Effect of adjuvants and route of immunizations on the immune response to recombinant plague antigens.

Authors:  Sabena Uddowla; Lucy C Freytag; John D Clements
Journal:  Vaccine       Date:  2007-10-02       Impact factor: 3.641

3.  Evaluation of combinatorial vaccines against anthrax and plague in a murine model.

Authors:  Amanda B DuBois; Lucy C Freytag; John D Clements
Journal:  Vaccine       Date:  2007-04-20       Impact factor: 3.641

4.  Protection conferred by recombinant Yersinia pestis antigens produced by a rapid and highly scalable plant expression system.

Authors:  Luca Santi; Anatoli Giritch; Chad J Roy; Sylvestre Marillonnet; Victor Klimyuk; Yuri Gleba; Robert Webb; Charles J Arntzen; Hugh S Mason
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-12       Impact factor: 11.205

5.  Antigen engineering can play a critical role in the protective immunity elicited by Yersinia pestis DNA vaccines.

Authors:  Shixia Wang; Innocent Mboudjeka; Jon D Goguen; Shan Lu
Journal:  Vaccine       Date:  2010-02-23       Impact factor: 3.641

6.  Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge.

Authors:  Shixia Wang; Jon D Goguen; Fusheng Li; Shan Lu
Journal:  Vaccine       Date:  2011-01-01       Impact factor: 3.641

7.  Cationic liposome-hyaluronic acid hybrid nanoparticles for intranasal vaccination with subunit antigens.

Authors:  Yuchen Fan; Preety Sahdev; Lukasz J Ochyl; Jonathan Akerberg; James J Moon
Journal:  J Control Release       Date:  2015-04-11       Impact factor: 9.776

8.  Different pathologies but equal levels of responsiveness to the recombinant F1 and V antigen vaccine and ciprofloxacin in a murine model of plague caused by small- and large-particle aerosols.

Authors:  Richard J Thomas; Daniel Webber; Aaron Collinge; Anthony J Stagg; Stephen C Bailey; Alejandro Nunez; Amanda Gates; Pramukh N Jayasekera; Rosa R Taylor; Steve Eley; Richard W Titball
Journal:  Infect Immun       Date:  2009-02-02       Impact factor: 3.441

9.  Intranasal immunization of mice with a bovine respiratory syncytial virus vaccine induces superior immunity and protection compared to those by subcutaneous delivery or combinations of intranasal and subcutaneous prime-boost strategies.

Authors:  John W Mapletoft; Laura Latimer; Lorne A Babiuk; Sylvia van Drunen Littel-van den Hurk
Journal:  Clin Vaccine Immunol       Date:  2009-10-28

10.  Effective plague vaccination via oral delivery of plant cells expressing F1-V antigens in chloroplasts.

Authors:  Philip A Arlen; Michael Singleton; Jeffrey J Adamovicz; Yi Ding; Abdolreza Davoodi-Semiromi; Henry Daniell
Journal:  Infect Immun       Date:  2008-05-27       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.